Does the media favor ROIV or MIRM?

In the previous week, Roivant Sciences had 7 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 9 mentions for Roivant Sciences and 2 mentions for Mirum Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.31 beat Mirum Pharmaceuticals' score of 1.26 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or INSM?

In the previous week, Insmed had 18 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 20 mentions for Insmed and 2 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat Insmed's score of 0.93 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 13 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or BNTX?

In the previous week, BioNTech had 6 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 8 mentions for BioNTech and 2 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat BioNTech's score of 0.63 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or GMAB?

In the previous week, Genmab A/S had 8 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 10 mentions for Genmab A/S and 2 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat Genmab A/S's score of 0.19 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Mirum Pharmaceuticals (MIRM) Competitors

$116.62 -2.24 (-1.88%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$118.08 +1.46 (+1.25%)

As of 06:33 AM Eastern

Compare

MIRM vs. ROIV, INSM, BNTX, VTRS, and GMAB

Should you buy Mirum Pharmaceuticals stock or one of its competitors? MarketBeat compares Mirum Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mirum Pharmaceuticals include Roivant Sciences (ROIV), Insmed (INSM), BioNTech (BNTX), Viatris (VTRS), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical products" industry.

How does Mirum Pharmaceuticals compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Mirum Pharmaceuticals has a net margin of -140.24% compared to Roivant Sciences' net margin of -3,629.19%. Mirum Pharmaceuticals' return on equity of -11.28% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Roivant Sciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

64.8% of Roivant Sciences shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Roivant Sciences had 7 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 9 mentions for Roivant Sciences and 2 mentions for Mirum Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.31 beat Mirum Pharmaceuticals' score of 1.26 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,965.03	-$299.77M	-$0.60	N/A
Mirum Pharmaceuticals	$521.31M	13.64	-$23.36M	-$13.61	N/A

Roivant Sciences currently has a consensus price target of $33.59, indicating a potential downside of 1.35%. Mirum Pharmaceuticals has a consensus price target of $143.40, indicating a potential upside of 22.96%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Mirum Pharmaceuticals beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Insmed?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Mirum Pharmaceuticals has a net margin of -140.24% compared to Insmed's net margin of -144.44%. Mirum Pharmaceuticals' return on equity of -11.28% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Insmed	-144.44%	-130.11%	-51.57%

Mirum Pharmaceuticals presently has a consensus price target of $143.40, suggesting a potential upside of 22.96%. Insmed has a consensus price target of $209.13, suggesting a potential upside of 95.41%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Insmed	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.96

Mirum Pharmaceuticals has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market. Comparatively, Insmed has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Mirum Pharmaceuticals has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	13.64	-$23.36M	-$13.61	N/A
Insmed	$606.42M	38.25	-$1.28B	-$5.75	N/A

In the previous week, Insmed had 18 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 20 mentions for Insmed and 2 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat Insmed's score of 0.93 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	13 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Insmed beats Mirum Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to BioNTech?

Mirum Pharmaceuticals (NASDAQ:MIRM) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

15.5% of BioNTech shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, BioNTech had 6 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 8 mentions for BioNTech and 2 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat BioNTech's score of 0.63 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

Mirum Pharmaceuticals has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	13.64	-$23.36M	-$13.61	N/A
BioNTech	$3.25B	7.18	-$1.29B	-$5.88	N/A

Mirum Pharmaceuticals currently has a consensus price target of $143.40, suggesting a potential upside of 22.96%. BioNTech has a consensus price target of $129.13, suggesting a potential upside of 40.11%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

BioNTech has a net margin of -44.39% compared to Mirum Pharmaceuticals' net margin of -140.24%. BioNTech's return on equity of -5.30% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
BioNTech	-44.39%	-5.30%	-4.62%

Summary

BioNTech beats Mirum Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Viatris?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

In the previous week, Mirum Pharmaceuticals had 2 more articles in the media than Viatris. MarketBeat recorded 2 mentions for Mirum Pharmaceuticals and 0 mentions for Viatris. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat Viatris' score of 0.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Mirum Pharmaceuticals	Positive
Viatris	Neutral

Mirum Pharmaceuticals presently has a consensus target price of $143.40, suggesting a potential upside of 22.96%. Viatris has a consensus target price of $17.50, suggesting a potential upside of 3.00%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Mirum Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Mirum Pharmaceuticals has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market. Comparatively, Viatris has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

Mirum Pharmaceuticals has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	13.64	-$23.36M	-$13.61	N/A
Viatris	$14.30B	1.38	-$3.51B	-$0.26	N/A

79.9% of Viatris shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Viatris has a net margin of -2.04% compared to Mirum Pharmaceuticals' net margin of -140.24%. Viatris' return on equity of 19.04% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Viatris	-2.04%	19.04%	7.62%

Summary

Mirum Pharmaceuticals beats Viatris on 10 of the 17 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Genmab A/S?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Genmab A/S has a net margin of 21.05% compared to Mirum Pharmaceuticals' net margin of -140.24%. Genmab A/S's return on equity of 15.34% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Genmab A/S	21.05%	15.34%	8.94%

Mirum Pharmaceuticals currently has a consensus price target of $143.40, suggesting a potential upside of 22.96%. Genmab A/S has a consensus price target of $38.21, suggesting a potential upside of 36.92%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Mirum Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

In the previous week, Genmab A/S had 8 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 10 mentions for Genmab A/S and 2 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat Genmab A/S's score of 0.19 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.1% of Genmab A/S shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	13.64	-$23.36M	-$13.61	N/A
Genmab A/S	$3.72B	4.68	$963M	$1.32	21.14

Summary

Genmab A/S beats Mirum Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Mirum Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRM vs. The Competition

Export

Metric	Mirum Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.25B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-8.57	20.49	27.07	23.94
Price / Sales	13.64	300.33	512.71	90.33
Price / Cash	2,331.54	60.31	26.68	47.25
Price / Book	19.06	7.92	10.63	6.14
Net Income	-$23.36M	$23.81M	$3.60B	$331.74M
7 Day Performance	-3.53%	-1.09%	-1.24%	-1.82%
1 Month Performance	8.86%	2.56%	1.09%	-1.45%
1 Year Performance	124.49%	42.16%	23.66%	16.32%

Mirum Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRM Mirum Pharmaceuticals	3.2246 of 5 stars	$116.62 -1.9%	$143.40 +23.0%	+124.6%	$7.25B	$521.31M	N/A	140
ROIV Roivant Sciences	1.8589 of 5 stars	$36.09 -0.6%	$33.59 -6.9%	+197.6%	$26.12B	$8.26M	N/A	860
INSM Insmed	4.0861 of 5 stars	$116.53 +3.3%	$211.86 +81.8%	+4.3%	$24.46B	$606.42M	N/A	1,664	Analyst Forecast
BNTX BioNTech	4.3308 of 5 stars	$93.53 -0.8%	$129.13 +38.1%	-16.2%	$23.84B	$3.25B	N/A	7,807	News Coverage Analyst Upgrade
VTRS Viatris	1.889 of 5 stars	$16.66 -1.8%	$17.50 +5.0%	+91.3%	$19.75B	$14.30B	N/A	30,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRM) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. ROIV, INSM, BNTX, VTRS, and GMAB

How does Mirum Pharmaceuticals compare to Roivant Sciences?

Summary

How does Mirum Pharmaceuticals compare to Insmed?

Summary

How does Mirum Pharmaceuticals compare to BioNTech?

Summary

How does Mirum Pharmaceuticals compare to Viatris?

Summary

How does Mirum Pharmaceuticals compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. ROIV, INSM, BNTX, VTRS, and GMAB

How does Mirum Pharmaceuticals compare to Roivant Sciences?

Is ROIV or MIRM more profitable?

Which has more risk and volatility, ROIV or MIRM?

Do insiders & institutionals have more ownership in ROIV or MIRM?

Does the media favor ROIV or MIRM?

Which has higher valuation & earnings, ROIV or MIRM?

Do analysts prefer ROIV or MIRM?

Summary

How does Mirum Pharmaceuticals compare to Insmed?

Is MIRM or INSM more profitable?

Do analysts recommend MIRM or INSM?

Which has more volatility & risk, MIRM or INSM?

Which has higher earnings and valuation, MIRM or INSM?

Does the media prefer MIRM or INSM?

Summary

How does Mirum Pharmaceuticals compare to BioNTech?

Do institutionals and insiders have more ownership in MIRM or BNTX?

Does the media prefer MIRM or BNTX?

Which has more risk & volatility, MIRM or BNTX?

Which has preferable valuation and earnings, MIRM or BNTX?

Do analysts recommend MIRM or BNTX?

Is MIRM or BNTX more profitable?

Summary

How does Mirum Pharmaceuticals compare to Viatris?

Does the media prefer MIRM or VTRS?

Do analysts prefer MIRM or VTRS?

Which has more volatility & risk, MIRM or VTRS?

Which has stronger earnings & valuation, MIRM or VTRS?

Do insiders and institutionals have more ownership in MIRM or VTRS?

Is MIRM or VTRS more profitable?

Summary

How does Mirum Pharmaceuticals compare to Genmab A/S?

Is MIRM or GMAB more profitable?

Do analysts prefer MIRM or GMAB?

Which has more risk and volatility, MIRM or GMAB?

Does the media prefer MIRM or GMAB?

Do insiders & institutionals have more ownership in MIRM or GMAB?

Which has better valuation & earnings, MIRM or GMAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools